Semler Scientific Q1 2025: Revenues Down 44%, Reports $64.7M Net Loss, EPS at -$6.74

Reuters
05-14
Semler Scientific Q1 2025: Revenues Down 44%, Reports $64.7M Net Loss, EPS at -$6.74

Semler Scientific Inc. reported its financial results for the first quarter ended March 31, 2025. The company experienced a significant decline in revenues, reporting $8.8 million, which marks a 44% decrease compared to the same period last year. The cost of revenues was $0.9 million, reflecting a 25% year-over-year decrease. The company also reported a net loss of $64.7 million, or $6.74 per basic and diluted share, compared to a net income of $6.1 million for the first quarter of 2024. This change represents a notable downturn in the company's financial performance. Semler Scientific's income tax benefit for the quarter was $10.2 million, with an effective tax benefit rate of 14%, compared to an expense of $1.7 million, or an effective tax rate of 22%, in the first quarter of 2024. The company's two largest customers, including their affiliates, accounted for 42% and 32% of the revenues for the first quarter of 2025, respectively. In 2024, its three largest customers contributed 45%, 25%, and 11% to the first quarter revenues. In addition to the financial results, Semler Scientific announced that it will provide a business update on its near-term strategies during a conference call, with the information being accessible through its website dashboard.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Semler Scientific Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY87093) on May 13, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10